title: Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate essential hypertension.
abstract: Twenty-four patients with mild-to-moderate hypertension (19 women, 5 men; mean age of 49 +/- 9.1 years) completed a 2-week washout phase followed by 1 week of single-blind placebo. Patients were then given isradipine at 2.5 mg twice daily, which was increased to up to 7.5 mg twice daily according to the blood pressure response, over a 12-month period. Thirteen patients completed the trial. The supine and sitting blood pressure decreased to normal levels within 6 weeks of starting active treatment. Heart rate remained unchanged. Plasma cholesterol and triglycerides did not change significantly. Plasma high-density lipoprotein (HDL) cholesterol increased significantly (p less than 0.05) and a decrease (NS) was observed in low-density lipoprotein (LDL) cholesterol and in the LDL/HDL cholesterol ratio. Very-low-density lipoprotein (VLDL) cholesterol did not change, nor did other biochemical laboratory tests, or electrocardiographic and echocardiographic parameters. The most notable side effects were headache (n = 1), flushing (n = 1), palpitations (n = 3), and pretibial edema (n = 1). In conclusion, our results indicate that isradipine is safe and effective in the long-term treatment of mild-to-moderate hypertension. It also appears to have beneficial effects on lipid metabolism.
authors.affiliation: Department of Cardiology, Istanbul University, Istanbul Medical Faculty, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Meriç
authors.forename: T
authors.initials: T
authors.lastname: Gören
authors.forename: D
authors.initials: D
authors.lastname: Atilgan
authors.forename: N
authors.initials: N
authors.lastname: Eren
authors.forename: A
authors.initials: A
authors.lastname: Cubukçu
authors.forename: N
authors.initials: N
authors.lastname: Koylan
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004095:Dihydropyridines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017275:Isradipine; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D008055:Lipids; D017275:Isradipine